•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Exicure Inks $4.8M Asset Deal to Strengthen Balance Sheet
Exicure, Inc. Announces Agreement to Sell GPC-100 Program Assets to GPCRT Inc. for KRW 6.5 Billion
Comparing Shattuck Labs (NASDAQ:STTK) & Exicure (NASDAQ:XCUR)
Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance
Exicure Announces Board and Committee Changes
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions
Exicure, Inc. Reports Full Year 2025 Financial Results
Exicure, Inc. Reports Full Year 2025 Financial Results
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings
Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 42.7% in December
Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial
This BlackRock stock just rocketed 70%
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting